Paper Details

  1. Home
  2. Paper Details

Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.

Author: ChangChing-Mao, LiangChih-Sung, ShihPo-Hsuan, TangKuo-Tung, WangShuu-Jiun, YangCheng-Chia, YangChun-Pai, YauYun-Chain

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This network meta-analysis compared the effectiveness of lasmiditan, rimegepant, and ubrogepant versus triptans for acute migraine treatment. The new migraine-specific treatments were associated with higher odds of pain freedom and pain relief at 2 hours compared to placebo, but lower odds than most triptans. However, their lack of cardiovascular risks may make them an alternative option to triptans.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubrogepant). OBJECTIVE: To compare outcomes associated with the use of lasmiditan, r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506232/

データ提供：米国国立医学図書館（NLM）

New Migraine Treatments: A Desert of Relief

Greetings from Dr. Camel, your guide through the world of headache relief. This study compares the effectiveness of new migraine treatments, like lasmiditan, rimegepant, and ubrogepant, to traditional triptans. It's like comparing different oases in the desert of migraine, seeking the most effective source of relief.

Finding Relief in the Migraine Desert

This comprehensive review of clinical trials compares the efficacy of different migraine medications, analyzing data from thousands of patients. It's like mapping out the desert of migraine, identifying the most promising paths to relief. The researchers found that while both the new treatments and triptans offered relief from migraine pain, triptans generally provided more substantial pain relief. This is a crucial finding for migraine sufferers, offering valuable information for choosing the best treatment option.

Navigating the Options

This study provides valuable guidance for migraine sufferers and their healthcare providers. It's like having a compass and map of the migraine desert, helping you navigate the different treatment options. While triptans remain a viable option, the researchers highlight the potential benefits of the new treatments, particularly in terms of their cardiovascular safety profile. This information empowers patients and providers to make informed decisions about the best course of treatment.

Dr.Camel's Conclusion

This study provides a comprehensive overview of the current landscape of migraine treatment options, offering valuable insights for both patients and healthcare providers. As we continue to navigate the challenging desert of migraine, this research offers hope for finding new and effective ways to alleviate this debilitating condition.

Date :
  1. Date Completed 2022-01-11
  2. Date Revised 2022-01-11
Further Info :

Pubmed ID

34633423

DOI: Digital Object Identifier

PMC8506232

Related Literature

Article Analysis
・Effects of ubrogepant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.